Brief: C4 Therapeutics, Pfizer Partner on Trial Combining Cemsidomide and Elranatamab for Relapsed/Refractory Multiple Myeloma
01/10/2025 12:19
Oct 1 (Reuters) - C4 Therapeutics Inc CCCC.O: C4 THERAPEUTICS ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH PFIZER FOR THE COMBINATION OF CEMSIDOMIDE AND ELRANATAMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA C4 THERAPEUTICS INC - PFIZER TO SUPPLY ELRANATAMAB AT NO COST; C4T TO CONDUCT TRIAL Source text: ID:nGNX5F9S1h Further company coverage: CCCC.O ((Reuters.Briefs@thomsonreuters.com;))